138619-78-0

Basic information

• Product Name: 1H-Isoindole-1,3(2H)-dione, 2-(6-phenylhexyl)-
• CAS NO: 138619-78-0
• Molecular Formula: C20H21NO2
• Molecular Weight: 307.392
• Mol File: 138619-78-0.mol
• Article Data: 7

Chemical Properties

• CAS DataBase Reference: 1H-Isoindole-1,3(2H)-dione, 2-(6-phenylhexyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-Isoindole-1,3(2H)-dione, 2-(6-phenylhexyl)-(138619-78-0)
• EPA Substance Registry System: 1H-Isoindole-1,3(2H)-dione, 2-(6-phenylhexyl)-(138619-78-0)

Safety Data

• Hazardous Substances Data: 138619-78-0(Hazardous Substances Data)

Upstream product

• 104-52-9 phenylpropyl chloride 
• 88597-06-2 3-(phthalimido)propyl-p-toluenesulfonate 
• 2430-16-2 6-phenyl-1-hexanol 
• 5581-75-9 6-phenylhexanic acid 
• 136918-14-4 phthalimide 
• 56644-06-5 6-phenyl-1-hexylchloride 
• 1074-82-4 potassium phtalimide 

Downstream Products

• 120375-57-7 6-phenylhexan-1-amine hydrochloride 
• 143819-12-9 6-phenyl-1-hexyl isocyanate 
• 1245739-99-4 ST₃₉₁₃ 
• 98510-43-1 2-Amino-5-nitroso-6-(6-phenyl-hexylamino)-3H-pyrimidin-4-one 
• 17734-20-2 6-phenylhexylamine 

Relevant articles and documents

Nickel/Cobalt-Catalyzed C(sp3)-C(sp3) Cross-Coupling of Alkyl Halides with Alkyl Tosylates

The C(sp3)-C(sp3) cross-coupling of alkyl halides with alkyl tosylates has been developed by employing a combination of nickel and nucleophilic cobalt catalysts in the presence of a manganese reductant. This method provides a straightforward route to a diverse set of not only secondary-primary but also primary-primary C(sp3)-C(sp3) linkages under mild conditions without using alkyl-metallic reagents. Mechanistic studies suggest the formation of alkyl radicals from both alkyl halides and alkyl tosylates. Additionally, cross-coupling could be applied to the short-step synthesis of a histone deacetylase inhibitor, Vorinostat.

Fatty Acid Amide Hydrolase (FAAH), Acetylcholinesterase (AChE), and Butyrylcholinesterase (BuChE): Networked Targets for the Development of Carbamates as Potential Anti-Alzheimer's Disease Agents

The modulation of the endocannabinoid system is emerging as a viable avenue for the treatment of neurodegeneration, being involved in neuroprotective and anti-inflammatory processes. In particular, indirectly enhancing endocannabinoid signaling to therapeutic levels through FAAH inhibition might be beneficial for neurodegenerative disorders such as Alzheimer's disease, effectively preventing or slowing the progression of the disease. Hence, in the search for a more effective treatment for Alzheimer's disease, in this paper, the multitarget-directed ligand paradigm was applied to the design of carbamates able to simultaneously target the recently proposed endocannabinoid system and the classic cholinesterase system, and achieve effective dual FAAH/cholinesterase inhibitors. Among the two series of synthesized compounds, while some derivatives proved to be extremely potent on a single target, compounds 9 and 19 were identified as effective dual FAAH/ChE inhibitors, with well-balanced nanomolar activities. Thus, 9 and 19 might be considered as new promising candidates for Alzheimer's disease treatment.

SUBSTITUTED BENZOXAZOLONE DERIVATIVES AS ACID CERAMIDASE INHIBITORS, AND THEIR USE AS MEDICAMENTS

The present invention relates to substituted benzoxazolone derivatives as acid ceramidase inhibitors, pharmaceutical compositions containing these inhibitors and methods of inhibiting acid ceramidase for the treatment of disorders in which modulation of the levels of ceramide is clinically relevant. The invention also provides substituted benzoxazolone derivatives for use in the treatment of cancer, inflammation, pain, inflammatory pain or pulmonary diseases.